Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Wave Life Sciences Ltd. (WVE) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Wave Life Sciences Ltd.. Table 2 shows the detailed insider transactions. This company's CIK number is 1631574.
Total stock buying since 2015: $117,319,107.
Total stock sales since 2015: $43,539,431.
Total stock option exercises since 2015: $4,960,909.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 473,545 | $4,555,386 | 604,681 | $1,709,082 |
| 2024 | 2,791,930 | $22,335,440 | 517,686 | $6,779,512 | 308,332 | $1,013,016 |
| 2023 | 4,300,000 | $21,500,000 | 96,698 | $416,841 | 0 | $0 |
| 2022 | 9,480,052 | $20,382,111 | 156,500 | $313,087 | 0 | $0 |
| 2021 | 0 | $0 | 21,699 | $229,355 | 10,930 | $27,106 |
| 2020 | 0 | $0 | 293,556 | $3,523,280 | 225,000 | $558,000 |
| 2019 | 263,158 | $10,000,004 | 110,729 | $4,397,680 | 56,000 | $138,880 |
| 2018 | 0 | $0 | 230,493 | $10,970,889 | 211,229 | $1,427,125 |
| 2017 | 423,398 | $9,881,552 | 463,486 | $11,485,001 | 1,500 | $3,720 |
| 2016 | 0 | $0 | 52,000 | $868,400 | 34,000 | $83,980 |
| 2015 | 2,076,250 | $33,220,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 264,020 | $2,626,743 | 21,000 | $191,730 |
| 2025-06 | 0 | $0 | 30,000 | $208,500 | 0 | $0 |
| 2025-03 | 0 | $0 | 179,525 | $1,720,143 | 537,681 | $1,403,272 |
| 2025-01 | 0 | $0 | 0 | $0 | 46,000 | $114,080 |
| 2024-11 | 0 | $0 | 137,234 | $2,059,670 | 86,000 | $418,120 |
| 2024-10 | 0 | $0 | 299,310 | $4,189,552 | 154,122 | $425,736 |
| 2024-09 | 2,791,930 | $22,335,440 | 17,146 | $154,314 | 0 | $0 |
| 2024-08 | 0 | $0 | 48,366 | $279,555 | 0 | $0 |
| 2024-07 | 0 | $0 | 0 | $0 | 68,210 | $169,160 |
| 2024-04 | 0 | $0 | 15,630 | $96,421 | 0 | $0 |
| 2023-12 | 4,300,000 | $21,500,000 | 0 | $0 | 0 | $0 |
| 2023-08 | 0 | $0 | 37,062 | $176,118 | 0 | $0 |
| 2023-02 | 0 | $0 | 59,636 | $240,723 | 0 | $0 |
| 2022-06 | 9,480,052 | $20,382,111 | 0 | $0 | 0 | $0 |
| 2022-05 | 0 | $0 | 82,817 | $142,444 | 0 | $0 |
| 2022-02 | 0 | $0 | 73,683 | $170,643 | 0 | $0 |
| 2021-03 | 0 | $0 | 0 | $0 | 10,930 | $27,106 |
| 2021-02 | 0 | $0 | 21,699 | $229,355 | 0 | $0 |
| 2020-09 | 0 | $0 | 100,000 | $1,500,000 | 100,000 | $248,000 |
| 2020-08 | 0 | $0 | 25,000 | $300,000 | 25,000 | $62,000 |
| 2020-07 | 0 | $0 | 147,577 | $1,559,151 | 100,000 | $248,000 |
| 2020-02 | 0 | $0 | 20,979 | $164,129 | 0 | $0 |
| 2019-12 | 0 | $0 | 6,000 | $210,000 | 6,000 | $14,880 |
| 2019-11 | 0 | $0 | 30,039 | $947,219 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-22 | Bolno Paul (President and CEO) | Sale | 217,351 | 10.10 | 2,194,810 |
| 2025-08-22 | Verdine Gregory L. | Sale | 10,000 | 10.00 | 100,000 |
| 2025-08-15 | Tan Aik Na | Sale | 21,000 | 9.25 | 194,250 |
| 2025-08-15 | Tan Aik Na | Option Ex | 21,000 | 9.13 | 191,730 |
| 2025-08-13 | Henry Christian O | Sale | 9,670 | 8.81 | 85,192 |
| 2025-08-05 | Tan Aik Na | Sale | 1,127 | 8.75 | 9,861 |
| 2025-08-05 | Takanashi Ken | Sale | 4,872 | 8.75 | 42,630 |
| 2025-06-13 | Verdine Gregory L. | Sale | 30,000 | 6.95 | 208,500 |
| 2025-03-20 | Henry Christian O | Sale | 10,500 | 9.77 | 102,574 |
| 2025-03-20 | Henry Christian O | Option Ex | 10,500 | 9.13 | 95,865 |
| 2025-03-07 | Bolno Paul (President and CEO) | Sale | 169,025 | 9.57 | 1,617,569 |
| 2025-03-07 | Bolno Paul (President and CEO) | Option Ex | 169,025 | 2.48 | 419,182 |
| 2025-03-07 | Verdine Gregory L. | Option Ex | 133,402 | 2.48 | 330,836 |
| 2025-03-05 | Verdine Gregory L. | Option Ex | 133,000 | 2.48 | 329,840 |
| 2025-03-04 | Vargeese Chandra (See Remarks) | Option Ex | 91,754 | 2.48 | 227,549 |
| 2025-01-23 | Vargeese Chandra (See Remarks) | Option Ex | 46,000 | 2.48 | 114,080 |
| 2024-11-25 | Bolno Paul (President and CEO) | Sale | 50,000 | 15.00 | 750,000 |
| 2024-11-25 | Bolno Paul (President and CEO) | Option Ex | 50,000 | 2.48 | 124,000 |
| 2024-11-15 | Bolno Paul (President and CEO) | Sale | 51,234 | 14.32 | 733,670 |
| 2024-11-08 | Francis Chris (See Remarks) | Sale | 36,000 | 16.00 | 576,000 |
| 2024-11-08 | Francis Chris (See Remarks) | Option Ex | 36,000 | 8.17 | 294,120 |
| 2024-10-16 | Bolno Paul (President and CEO) | Sale | 90,474 | 15.00 | 1,357,110 |
| 2024-10-16 | Francis Chris (See Remarks) | Sale | 208,836 | 13.56 | 2,832,442 |
| 2024-10-16 | Francis Chris (See Remarks) | Option Ex | 129,122 | 2.82 | 363,736 |
| 2024-10-11 | Moran Kyle (Chief Financial Officer) | Option Ex | 25,000 | 2.48 | 62,000 |
| 2024-09-27 | Gsk Plc | Buy | 2,791,930 | 8.00 | 22,335,440 |
| 2024-09-25 | Moran Kyle (Chief Financial Officer) | Sale | 17,146 | 9.00 | 154,314 |
| 2024-08-21 | Bolno Paul (President and CEO) | Sale | 48,366 | 5.78 | 279,555 |
| 2024-07-22 | Vargeese Chandra (See Remarks) | Option Ex | 68,210 | 2.48 | 169,160 |
| 2024-04-03 | Moran Kyle (Chief Financial Officer) | Sale | 15,630 | 6.17 | 96,421 |
| 2023-12-11 | Shah Rajeev M. | Buy | 1,000,000 | 5.00 | 5,000,000 |
| 2023-12-07 | Gsk Plc | Buy | 3,300,000 | 5.00 | 16,500,000 |
| 2023-08-23 | Moran Kyle (Chief Financial Officer) | Sale | 37,062 | 4.75 | 176,118 |
| 2023-02-16 | Moran Kyle (Chief Financial Officer) | Sale | 9,729 | 4.04 | 39,305 |
| 2023-02-16 | Bolno Paul (President and CEO) | Sale | 29,400 | 4.04 | 118,776 |
| 2023-02-16 | Francis Chris (See Remarks) | Sale | 10,258 | 4.03 | 41,339 |
| 2023-02-16 | Vargeese Chandra (See Remarks) | Sale | 10,249 | 4.03 | 41,303 |
| 2022-06-16 | Shah Rajeev M. | Buy | 9,480,052 | 2.15 | 20,382,111 |
| 2022-05-05 | Panzara Michael A. (See Remarks) | Sale | 16,714 | 1.72 | 28,748 |
| 2022-05-05 | Moran Kyle (Chief Financial Officer) | Sale | 5,021 | 1.72 | 8,636 |
| 2022-05-05 | Bolno Paul (President and CEO) | Sale | 33,501 | 1.72 | 57,621 |
| 2022-05-05 | Francis Chris (See Remarks) | Sale | 10,867 | 1.72 | 18,691 |
| 2022-05-05 | Vargeese Chandra (See Remarks) | Sale | 16,714 | 1.72 | 28,748 |
| 2022-02-16 | Panzara Michael A. (See Remarks) | Sale | 10,603 | 2.31 | 24,492 |
| 2022-02-16 | Moran Kyle (Chief Financial Officer) | Sale | 9,204 | 2.31 | 21,261 |
| 2022-02-16 | Bolno Paul (President and CEO) | Sale | 33,150 | 2.32 | 76,908 |
| 2022-02-16 | Francis Chris (See Remarks) | Sale | 10,123 | 2.31 | 23,384 |
| 2022-02-16 | Vargeese Chandra (Chief Technology Officer) | Sale | 10,603 | 2.32 | 24,598 |
| 2021-03-24 | Moran Kyle (Chief Financial Officer) | Option Ex | 10,930 | 2.48 | 27,106 |
| 2021-02-16 | Panzara Michael A. (See Remarks) | Sale | 2,929 | 10.57 | 30,959 |
| 2021-02-16 | Moran Kyle (Chief Financial Officer) | Sale | 1,722 | 10.57 | 18,201 |
| 2021-02-16 | Bolno Paul (President and CEO) | Sale | 11,205 | 10.57 | 118,436 |
| 2021-02-16 | Francis Chris (See Remarks) | Sale | 2,698 | 10.57 | 28,517 |
| 2021-02-16 | Vargeese Chandra (Chief Technology Officer) | Sale | 3,145 | 10.57 | 33,242 |
| 2020-09-15 | Bolno Paul (President and CEO) | Sale | 100,000 | 15.00 | 1,500,000 |
| 2020-09-15 | Bolno Paul (President and CEO) | Option Ex | 100,000 | 2.48 | 248,000 |
| 2020-08-25 | Bolno Paul (President and CEO) | Sale | 25,000 | 12.00 | 300,000 |
| 2020-08-25 | Bolno Paul (President and CEO) | Option Ex | 25,000 | 2.48 | 62,000 |
| 2020-07-02 | Bolno Paul (President and CEO) | Sale | 147,577 | 10.56 | 1,559,151 |
| 2020-07-02 | Bolno Paul (President and CEO) | Option Ex | 100,000 | 2.48 | 248,000 |
| 2020-02-18 | Panzara Michael A. (Chief Medical Officer) | Sale | 2,981 | 7.85 | 23,400 |
| 2020-02-18 | Bolno Paul (President and CEO) | Sale | 11,451 | 7.85 | 89,890 |
| 2020-02-18 | Francis Chris (See Remarks) | Sale | 2,708 | 7.85 | 21,257 |
| 2020-02-18 | Vargeese Chandra (Senior VP, Drug Discovery) | Sale | 3,188 | 7.85 | 25,025 |
| 2020-02-03 | Gaiero David G (Interim CFO) | Sale | 651 | 7.00 | 4,557 |
| 2019-12-03 | Vargeese Chandra (Senior VP, Drug Discovery) | Sale | 6,000 | 35.00 | 210,000 |
| 2019-12-03 | Vargeese Chandra (Senior VP, Drug Discovery) | Option Ex | 6,000 | 2.48 | 14,880 |
| 2019-11-20 | Verdine Gregory L. (Director) | Sale | 30,039 | 31.53 | 947,219 |
| 2019-07-05 | Panzara Michael A. (Chief Medical Officer) | Sale | 3,058 | 27.07 | 82,780 |
| 2019-03-15 | Bolno Paul (President and CEO) | Sale | 50,000 | 45.64 | 2,282,000 |
| 2019-03-15 | Bolno Paul (President and CEO) | Option Ex | 50,000 | 2.48 | 124,000 |
| 2019-03-11 | Panzara Michael A. (Franchise Lead, Neurology) | Sale | 7,000 | 48.00 | 336,000 |
| 2019-02-19 | Regnante Keith (Chief Financial Officer) | Sale | 1,298 | 36.84 | 47,818 |
| 2019-02-19 | Panzara Michael A. (Franchise Lead, Neurology) | Sale | 1,837 | 36.84 | 67,673 |
| 2019-02-19 | Bolno Paul (President and CEO) | Sale | 7,733 | 36.92 | 285,525 |
| 2019-02-19 | Francis Chris (See Remarks) | Sale | 1,709 | 36.84 | 62,959 |
| 2019-02-19 | Vargeese Chandra (Senior VP, Drug Discovery) | Sale | 2,055 | 36.84 | 75,706 |
| 2019-01-24 | Kolchinsky Peter | Buy | 263,158 | 38.00 | 10,000,004 |
| 2018-11-14 | Verdine Gregory L. (Director) | Sale | 15,000 | 39.05 | 585,825 |
| 2018-09-25 | Francis Chris (See Remarks) | Sale | 10,543 | 56.00 | 590,408 |
| 2018-09-25 | Francis Chris (See Remarks) | Option Ex | 10,543 | 2.48 | 26,146 |
| 2018-09-24 | Regnante Keith (Chief Financial Officer) | Sale | 29,500 | 55.00 | 1,622,500 |
| 2018-09-24 | Regnante Keith (Chief Financial Officer) | Option Ex | 29,500 | 20.89 | 616,255 |
| 2018-09-24 | Francis Chris (See Remarks) | Sale | 1,032 | 56.00 | 57,792 |
| 2018-09-24 | Francis Chris (See Remarks) | Option Ex | 1,032 | 2.48 | 2,559 |
| 2018-09-24 | Vargeese Chandra (Senior VP, Drug Discovery) | Sale | 3,000 | 55.00 | 165,000 |
| 2018-09-24 | Vargeese Chandra (Senior VP, Drug Discovery) | Option Ex | 3,000 | 2.48 | 7,440 |
| 2018-07-09 | Francis Chris (See Remarks) | Sale | 24,496 | 37.73 | 924,356 |
| 2018-07-09 | Francis Chris (See Remarks) | Option Ex | 24,496 | 2.48 | 60,750 |
| 2018-06-01 | Francis Chris (See Remarks) | Sale | 24,496 | 48.00 | 1,175,808 |
| 2018-06-01 | Francis Chris (See Remarks) | Option Ex | 24,496 | 2.48 | 60,750 |
| 2018-05-30 | Bolno Paul (President and CEO) | Sale | 20,250 | 45.00 | 911,250 |
| 2018-05-30 | Bolno Paul (President and CEO) | Option Ex | 20,250 | 2.48 | 50,220 |
| 2018-05-30 | Francis Chris (See Remarks) | Sale | 24,496 | 45.50 | 1,114,568 |
| 2018-05-30 | Francis Chris (See Remarks) | Option Ex | 24,496 | 2.48 | 60,750 |
| 2018-05-29 | Bolno Paul (President and CEO) | Sale | 3,145 | 45.00 | 141,525 |
| 2018-05-29 | Bolno Paul (President and CEO) | Option Ex | 3,145 | 2.48 | 7,799 |
| 2018-05-25 | Bolno Paul (President and CEO) | Sale | 8,316 | 45.00 | 374,220 |
| 2018-05-25 | Bolno Paul (President and CEO) | Option Ex | 8,316 | 2.48 | 20,623 |
| 2018-05-02 | Bolno Paul (President and CEO) | Sale | 18,289 | 45.00 | 823,005 |
| 2018-05-02 | Bolno Paul (President and CEO) | Option Ex | 18,289 | 2.48 | 45,356 |
| 2018-02-20 | Francis Chris (See Remarks) | Sale | 11,504 | 55.95 | 643,648 |
| 2018-02-20 | Francis Chris (See Remarks) | Option Ex | 11,504 | 2.48 | 28,529 |
| 2018-02-16 | Regnante Keith (Chief Financial Officer) | Sale | 316 | 51.85 | 16,384 |
| 2018-02-16 | Panzara Michael A. (Franchise Lead, Neurology) | Sale | 511 | 52.10 | 26,623 |
| 2018-02-16 | Bolno Paul (President and CEO) | Sale | 2,714 | 51.31 | 139,268 |
| 2018-02-16 | Francis Chris (See Remarks) | Sale | 10,135 | 53.40 | 541,209 |
| 2018-02-16 | Francis Chris (See Remarks) | Option Ex | 9,412 | 2.48 | 23,341 |
| 2018-02-15 | Panzara Michael A. (Franchise Lead, Neurology) | Sale | 18,750 | 50.00 | 937,500 |
| 2018-02-15 | Panzara Michael A. (Franchise Lead, Neurology) | Option Ex | 18,750 | 21.69 | 406,687 |
| 2018-02-15 | Vargeese Chandra (See Remarks) | Sale | 2,000 | 50.00 | 100,000 |
| 2018-02-15 | Vargeese Chandra (See Remarks) | Option Ex | 2,000 | 2.48 | 4,960 |
| 2018-01-23 | Vargeese Chandra (See Remarks) | Sale | 2,000 | 40.00 | 80,000 |
| 2018-01-23 | Vargeese Chandra (See Remarks) | Option Ex | 2,000 | 2.48 | 4,960 |
| 2017-11-22 | Vargeese Chandra (See Remarks) | Sale | 1,500 | 35.00 | 52,500 |
| 2017-11-22 | Vargeese Chandra (See Remarks) | Option Ex | 1,500 | 2.48 | 3,720 |
| 2017-11-14 | Kolchinsky Peter | Buy | 23,398 | 24.00 | 561,552 |
| 2017-11-13 | Kolchinsky Peter | Buy | 400,000 | 23.30 | 9,320,000 |
| 2017-09-18 | Kagoshima Shinsangyo Sousei Investment Limited Partnership (10% Owner) | Sale | 6,362 | 24.19 | 153,896 |
| 2017-09-15 | Kagoshima Shinsangyo Sousei Investment Limited Partnership (10% Owner) | Sale | 14,385 | 24.22 | 348,404 |
| 2017-07-12 | Panzara Michael A. (Franchise Lead, Neurology) | Sale | 7,414 | 16.67 | 123,621 |
| 2017-03-29 | Kagoshima Shinsangyo Sousei Investment Limited Partnership (10% Owner) | Sale | 433,825 | 24.91 | 10,806,580 |
| 2016-12-07 | Guerciolini Roberto (See Remarks) | Option Ex | 24,000 | 2.47 | 59,280 |
| 2016-08-19 | Guerciolini Roberto (See Remarks) | Option Ex | 5,000 | 2.47 | 12,350 |
| 2016-07-28 | Guerciolini Roberto (See Remarks) | Option Ex | 5,000 | 2.47 | 12,350 |
| 2016-06-15 | Verdine Gregory L. (Director) | Sale | 52,000 | 16.70 | 868,400 |
| 2015-11-16 | Shin Nippon Biomedical Laboratories, Ltd. (10% Owner) | Buy | 125,000 | 16.00 | 2,000,000 |
| 2015-11-16 | Kagoshima Shinsangyo Sousei Investment Limited Partnership (10% Owner) | Buy | 76,250 | 16.00 | 1,220,000 |
| 2015-11-16 | Ra Capital Healthcare Fund Lp | Buy | 1,875,000 | 16.00 | 30,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of WVE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Wave Life Sciences Ltd. (symbol WVE, CIK number 1631574) see the Securities and Exchange Commission (SEC) website.